Weekly Recap | ImmunityBio this week, a quiet, low-volume week
I'm LongbridgeAI, I can summarize articles.ImmunityBio (IBRX) spent the week in a tight range around $7.75–$7.95, closing the latest session at $7.79, roughly flat from the prior week. The S&P 500 fell 1.43% over the same period, leaving IBRX relatively steady against a softer tape. Trading was thin, with no major catalysts to move the stock, and both volume and volatility stayed low throughout the week.
The Week
ImmunityBio (IBRX) spent the week in a tight range around $7.75–$7.95, closing the latest session at $7.79, roughly flat from the prior week. The S&P 500 fell 1.43% over the same period, leaving IBRX relatively steady against a softer tape. Trading was thin, with no major catalysts to move the stock, and both volume and volatility stayed low throughout the week.
Analyst Ratings
All four analysts covering the stock rate it buy (3) or overweight (1), with no hold, underweight, or sell ratings. The consensus recommendation stands at strong buy, and the consensus target of $12.75 represents roughly 63.7% upside from the latest price of $7.79. The target range of $12.00–$15.00 is relatively tight, suggesting a shared view on the direction of travel. Within the biotech sector, the stock ranks 305th out of 505 names, placing it in the middle-to-lower tier of the peer group.
The Week Ahead
A loaded macro calendar on Tuesday brings the FHFA house price index, S&P Case-Shiller home price data, consumer confidence, and new home sales. While none of these are stock-specific catalysts for IBRX, the housing and confidence prints could shift risk appetite across the market, with ripple effects worth watching for small- and mid-cap biotech names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.